RVL Pharmaceuticals plc Finite-Lived Intangible Asset, Expected Amortization, after Year Five
RVL Pharmaceuticals plc had Finite-Lived Intangible Asset, Expected Amortization, after Year Five of $6.25 million as of 2021-03-31, per its 10-Q filed 2021-05-13.
Discontinued › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive · last filed 2021-05-13
- 2021-03-31: Finite-Lived Intangible Asset, Expected Amortization, after Year Five $6.25M.
- 2020-12-31: Finite-Lived Intangible Asset, Expected Amortization, after Year Five $7.32M.
- 2020-09-30: Finite-Lived Intangible Asset, Expected Amortization, after Year Five $19.50M.
- 2020-06-30: Finite-Lived Intangible Asset, Expected Amortization, after Year Five $19.46M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, after Year Five |
|---|---|
| 2021-03-31 | $6.25M 10-Q · filed 2021-05-13 |
| 2020-12-31 | $7.32M 10-K · filed 2021-03-30 |
| 2020-09-30 | $19.50M 10-Q · filed 2020-11-10 |
| 2020-06-30 | $19.46M 10-Q · filed 2020-08-11 |
| 2020-03-31 | $20.20M 10-Q · filed 2020-05-12 |
| 2019-12-31 | $20.20M 10-K · filed 2020-03-19 |
| 2019-09-30 | $50.03M 10-Q · filed 2019-11-14 |
| 2019-06-30 | $70.91M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $136.69M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $122.92M 8-K · filed 2019-12-20 |
| 2018-09-30 | $162.85M 10-Q · filed 2018-11-08 |